dexrazoxane (Zinecard, Cardioxane)

Introduction

Tradename: Zinecard.

Indications

• reduction in the incidence & severity of cardiomyopathy associated with doxorubicin administration) women with metastatic breast cancer who have received a total dose of doxorubicin of 300 mg/m2 & would benefit from continued doxorubicin therapy
• NOT recommended for use with initiation of doxorubicin therapy

Contraindications

• NOT for use with chemotherapeutic regimens that do not include an anthracycline

Powder for injection: lyophilized 250 & 500 mg (10 mg/mL when reconstituted)

Monitor

complete blood count (CBC)

Adverse effects

• difficult to dissect from adverse effects of chemotherapeutic regimens
• pain on injection
• myelosuppression
  • more severe leukopenia, granulocytopenia, thrombocytopenia at nadir
  • recovery counts unaffected
• urticaria (1-2%)
• recall skin reaction (1-2%)
• extravasation (1-2%)

Drug interactions

• other myelosuppressive agents

More general terms

• razoxane

Additional terms

• doxorubicin (Adriamycin, Rubex)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71384
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=30623